Our Pricing

Understanding Wegovy UK Cost: Private Prescription Options

Published on: June 03, 2026

When researching wegovy uk cost private prescription options, transparency matters. At Cured Pharmacy, you'll find genuine UK-licensed Wegovy (semaglutide) from £79.00 with upfront pricing, free clinical consultation by UK prescribers, and discreet next-day delivery. All prescription treatments require assessment by our registered clinical team to ensure suitability and safety.

Wegovy UK Cost: What Determines Your Private Prescription Price

The cost of Wegovy in the UK varies based on dosage strength and treatment duration. At Cured Pharmacy, Wegovy starts from £79.00 with final pricing determined by your prescribed dose following clinical assessment [1]. Unlike some providers, we display transparent pricing before you begin your consultation, ensuring no hidden fees or unexpected charges.

Your UK prescriber will assess your BMI, medical history, and weight loss goals to determine the appropriate starting dose. Wegovy follows a gradual dose escalation schedule, beginning at 0.25mg weekly and increasing over 16-20 weeks to the maintenance dose of 2.4mg, subject to tolerability and clinical response [2].

Private prescription costs typically include the medication itself, clinical consultation, and dispensing fees. At Cured Pharmacy, our consultation is completely free, and we guarantee the lowest prices in the UK. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures every prescription meets MHRA standards for safety and authenticity.

Factors Affecting Wegovy Prescription Costs

Several clinical factors influence your treatment cost: prescribed dose strength, treatment duration, and whether you're continuing from a lower maintenance dose. Patients typically remain on the 2.4mg maintenance dose long-term for sustained weight management, though your prescriber may adjust based on individual response and tolerability [1][2].

How Wegovy (Semaglutide) Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone your body produces after eating [2]. This medication works through multiple mechanisms: it slows gastric emptying, reduces appetite signals to the brain, and enhances feelings of fullness after meals.

In the landmark STEP clinical trial programme, adults using Wegovy 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. Participants also experienced improvements in cardiovascular risk markers, including blood pressure and lipid profiles, though individual results vary based on adherence and lifestyle factors.

Unlike older weight loss medications that work solely through fat absorption or appetite suppression, semaglutide addresses the underlying hormonal regulation of hunger and satiety. This mechanism explains why clinical trials demonstrated sustained weight loss when combined with reduced-calorie diet and increased physical activity [2][3].

Wegovy vs Mounjaro: Comparing UK Weight Loss Injections

Both Wegovy and Mounjaro are once-weekly injectable medications licensed by the MHRA for chronic weight management in adults with obesity or overweight plus weight-related conditions. The key difference lies in their mechanism: Wegovy activates GLP-1 receptors only, whilst Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist [1][4].

Clinical trial data suggests tirzepatide may produce greater average weight loss than semaglutide. In the SURMOUNT-1 trial, participants on the highest tirzepatide dose (15mg) achieved average weight reduction of 22.5% over 72 weeks, compared to 14.9% with semaglutide 2.4mg in STEP trials [1][2]. However, both medications require prescription assessment, and individual response varies significantly.

Your UK prescriber will consider several factors when recommending treatment: your medical history, previous weight loss attempts, tolerance for gastrointestinal side effects, and cost considerations. Some patients respond better to single-pathway GLP-1 agonists, whilst others may benefit from dual-receptor activation, subject to clinical suitability [4].

Choosing Between Wegovy and Alternative Treatments

Beyond injectable GLP-1 medications, UK patients have access to other prescription weight loss treatments including Saxenda (daily liraglutide injection), Orlistat (fat absorption inhibitor), and Mysimba (combination appetite suppressant). Your prescriber will discuss all suitable options during your free consultation, considering efficacy data, administration preferences, and individual health factors [3][5].

Starting Your Wegovy UK Private Prescription at Cured Pharmacy

Our streamlined online consultation takes under three minutes and is reviewed by UK-registered prescribers within hours. You'll complete a confidential medical questionnaire covering your weight history, current medications, and relevant health conditions. This ensures Wegovy is clinically appropriate and safe for you.

If approved, your prescription is dispensed by our GPhC-registered pharmacy (registration 9012511) and dispatched in 100% discreet packaging via next-day courier. All medications are genuine UK-licensed products sourced directly from licensed wholesalers, never grey-market imports. You'll receive complete dosing instructions, injection technique guidance, and access to our clinical support team.

Wegovy requires refrigeration before first use and can be stored at room temperature for up to 28 days once in use. Each pen contains four weekly doses, and you'll receive clear instructions on injection sites (abdomen, thigh, or upper arm) and proper rotation to minimise injection site reactions [2].

Wegovy Side Effects and Safety Considerations

The most common side effects of Wegovy are gastrointestinal: nausea, diarrhoea, vomiting, and constipation, particularly during dose escalation [2]. These symptoms typically improve as your body adjusts to the medication. Starting at a low dose and gradually increasing over 16-20 weeks helps minimise these effects.

Serious but rare side effects include pancreatitis, gallbladder problems, and hypoglycaemia (particularly in patients taking other diabetes medications). Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2][6]. Your prescriber will screen for these conditions during assessment.

Clinical trials excluded pregnant and breastfeeding women, and Wegovy should be discontinued at least two months before planned pregnancy due to the long washout period [6]. Women of childbearing potential should use effective contraception during treatment. Always inform your prescriber of all current medications, as semaglutide may affect absorption of oral medications due to delayed gastric emptying.

Managing Side Effects During Treatment

If you experience persistent nausea or vomiting, eating smaller, more frequent meals and avoiding high-fat foods can help. Stay well-hydrated, particularly if experiencing diarrhoea or vomiting. Contact our clinical team if side effects become severe or don't improve after several weeks, as dose adjustment may be appropriate [2].

Maximising Weight Loss Results with Wegovy

Wegovy is licensed as an adjunct to reduced-calorie diet and increased physical activity, not as monotherapy [2]. Clinical trial participants received intensive behavioural support, including dietary counselling and exercise programmes. Whilst the medication significantly enhances weight loss beyond lifestyle changes alone, optimal results require sustained commitment to healthier habits.

NICE guidelines recommend aiming for gradual weight loss of 0.5-1kg per week through a calorie deficit of approximately 600kcal daily [7]. Focus on nutrient-dense whole foods, adequate protein intake (to preserve muscle mass during weight loss), and regular physical activity including both cardiovascular exercise and resistance training. Your prescriber can provide personalised guidance based on your starting point and goals.

Weight loss typically peaks between 60-68 weeks of treatment, with most patients achieving their maximum response by this timepoint [2]. After reaching goal weight, many patients continue Wegovy at maintenance dose to prevent weight regain, though this requires ongoing prescription review. Discontinuation often results in gradual weight regain, highlighting the chronic nature of obesity management [3].

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
6. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
7. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE guideline. Retrieved from https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, diet, and lifestyle modifications.